<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2414">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129735</url>
  </required_header>
  <id_info>
    <org_study_id>20227Teatis</org_study_id>
    <nct_id>NCT05129735</nct_id>
  </id_info>
  <brief_title>An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.</brief_title>
  <official_title>An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teatis, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Citruslabs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teatis, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label single-arm observational trial to study the effectiveness of a&#xD;
      commercially available meal-replacement shake and its effect on the quality of life in&#xD;
      individuals with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label single-arm observational trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of quality of life score from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Survey based quality of life measure on a scale from 0-5 (0=lowest possible score, 5=highest possible score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in a1c levels from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in a1c biomarkers measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in blood glucose from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in blood glucose biomarkers measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in insulin levels from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in insulin levels measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in total cholesterol levels from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in total cholesterol measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in triglyceride levels from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in triglyceride measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in HDL cholesterol levels from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in HDL cholesterol measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in LDL cholesterol levels from baseline to 12-weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in LDL cholesterol measured with an at-home blood test after 12 weeks compared to baseline results.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Meal replacement shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teatis meal replacement shake</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meal replacement shake</intervention_name>
    <description>Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.</description>
    <arm_group_label>Meal replacement shake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female between 18-75 years old&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes for at least 3 months&#xD;
&#xD;
          -  HbA1c of 7.5 to 10% inclusive&#xD;
&#xD;
          -  BMI of 27 to 40 kg/m2&#xD;
&#xD;
          -  If on any medication, treated with a stable dose for at least 90 days&#xD;
&#xD;
          -  Must be in good health (don't report any medical conditions asked in the screening&#xD;
             questionnaire)&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Must have a Glucometer at home&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes&#xD;
&#xD;
          -  Have a history of severe hypoglycemia or hyperglycemia requiring hospitalization&#xD;
             within the prior 6 months&#xD;
&#xD;
          -  Use of dietary supplements or meal-replacement shakes targeted at diabetes and&#xD;
             unwilling to stop using them for the duration of the study&#xD;
&#xD;
          -  Allergies to any test product ingredients&#xD;
&#xD;
          -  Has any of the following medical conditions:&#xD;
&#xD;
          -  Oncological conditions&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Cardiovascular disease: any hospitalization within the past 3 months&#xD;
&#xD;
          -  Multiple Sclerosis&#xD;
&#xD;
          -  Gastrointestinal conditions such as Celiac disease, Crohn's disease, etc.&#xD;
&#xD;
          -  Any other severe chronic disease&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Females who are pregnant, want to become pregnant for the duration of the study, or&#xD;
             who are breastfeeding during the course of the study&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to screening&#xD;
&#xD;
          -  Participating in an investigational health product research study&#xD;
&#xD;
          -  Any disorder, unwillingness, or inability, which in the investigator's opinion, might&#xD;
             jeopardize the individual's safety or compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Mitschke, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citruslabs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Renner, MSc</last_name>
    <phone>4242450284</phone>
    <email>hello@citruslabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Citruslabs</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick Renner, MSc</last_name>
      <phone>424-245-0284</phone>
      <email>hello@citruslabs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

